Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

The Journal of biological chemistry - 4 Nov 2005

Lin Chao, Gates Cynthia A, Rao B Govinda, Brennan Debra L, Fulghum John R, Luong Yu-Ping, Frantz J Daniel, Lin Kai, Ma Sue, Wei Yun-Yi, Perni Robert B, Kwong Ann D

Abstract excerpt

VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease and has recently been shown to possess antiviral activity in a phase I trial in patients chronically infected with genotype 1 HCV. In a previous study, we described in vitro resistance mutations against either VX-950 or another HCV NS3.4A protease inhibitor, BILN 2061. Single amino acid substitutions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macrocyclic Compounds

Share to Oligopeptides

Share to Quinolines

Share to Replicon

Share to Serine Proteinase Inhibitors

Share to Thiazoles

Source

Identifiers

PMID: 16087668
DOI: 10.1074/jbc.M506462200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.PMID 16087668Read ↗

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.Semantic proximity Read ↗

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.Semantic proximity Read ↗

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsSemantic proximity Read ↗

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Semantic proximity Read ↗

Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.Semantic proximity Read ↗

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.Semantic proximity Read ↗

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Semantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.Semantic proximity Read ↗

Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.Semantic proximity Read ↗

Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.